22 min listen
Role of PARP Inhibition in Ovarian Cancer with Dr Thomas Herzog
Role of PARP Inhibition in Ovarian Cancer with Dr Thomas Herzog
ratings:
Length:
50 minutes
Released:
Dec 21, 2022
Format:
Podcast episode
Description
Dr Thomas Herzog from the University of Cincinnati Medical Center in Cincinnati, Ohio, discusses updates and recent changes in the use of PARP inhibitors for ovarian cancer.
CME information and select publications here (http://www.researchtopractice.com/OncologyTodayOvarianPARP22).
CME information and select publications here (http://www.researchtopractice.com/OncologyTodayOvarianPARP22).
Released:
Dec 21, 2022
Format:
Podcast episode
Titles in the series (100)
Dr Tom Lynch on Adjuvant EGFR TKIs in Lung Cancer and COVID-19 in Seattle: Dr Tom Lynch comments on the current status of oncology research and data soon to be presented from a Phase III trial evaluating the EGFR TKI osimertinib as adjuvant therapy for patients with non-small cell lung cancer and EGFR tumor mutations. by Oncology Today with Dr Neil Love